Primary Biliary Cholangitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 6 and 23 years old
- You have been formally diagnosed with either autoimmune hepatitis (AIH) or primary sclerosing cholangitis (PSC), which are liver conditions where the immune system or bile ducts are affected (confirm with trial site)
Who may not be able to join:
- You have previously had a liver transplant
- You have chronic Hepatitis B or Hepatitis C that has not been treated
- You are currently pregnant
- You are unable to have an MRI scan for medical reasons, such as having a pacemaker, metal implants in your body, or severe claustrophobia (fear of enclosed spaces)
- You have been diagnosed with cystic fibrosis or biliary atresia (a condition affecting the bile ducts)
- You have been diagnosed with cardiac hepatopathy, which is liver damage caused by heart problems (confirm with trial site)
- You have been diagnosed with Wilson's disease, Alpha-1 Antitrypsin deficiency, or Glycogen storage disease, which are conditions that affect how the body processes certain substances
- You have a serious skin condition that could be made worse by a procedure called MREL, such as Epidermolysis bullosa (a condition that causes very fragile skin) (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Alexander Miethke, MD, Cincinnati Childrens Hospital Medical Center
Phone: 513-636-8948
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change of intrahepatic bile duct irregularities between V0 (baseline visit) and V1 (visit after12 months) or V2 (visit after 24 months).; Change of extra-hepatic duct irregularities between V0 (baseline visit) and V1 (visit after 12 months) or V2 (visit after 24 months).; Mean shear stiffness of the liver; long-term clinical outcomes: survival with the native liver; long-term clinical outcomes: hospital admissions for cholangitis; long-term clinical outcomes:endoscopic interventions for biliary strictures; long-term clinical outcomes:diagnosis of cholangiocarcinoma; long-term clinical outcomes...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.